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A B S T R A C T
This systematic review is to evaluate the eﬃcacy and safety of Chinese herbal medicine (CHM) for people
with insomnia. Randomized controlled trials (RCTs) investigating oral CHM alone or in combination with
conventional therapies for primary insomnia were identiﬁed by searching English and Chinese publica-
tions and databases of clinical trial registration. Risk of bias was assessed according to the Cochrane
Handbook 5.1. Meta-analysis was conducted using RevMan 5.2.4. Seventy-nine trials (7886 partici-
pants) were ﬁnally included in the review, and 76 were included in the meta-analysis. Twenty-seven trials
reported the methods of random sequence generation, and ﬁve of them used the allocation conceal-
ment. Blinding of participants and personnel were used in 10 studies. The main meta-analysis showed
that CHM alone was more effective than placebo by reducing scores of Pittsburgh Sleep Quality Index
(mean difference, MD: −3.06, 95% conﬁdence interval, CI: −5.14 to −0.98, I2 = 97%) and benzodiazepine
drugs (BZDs) (MD: −1.94, 95% CI: −2.45 to −1.43, I2 = 96%). The effect was also seen when CHM was com-
bined with BZDs compared with placebo plus BZDs (MD: −1.88, 95% CI: −2.78 to −0.97, I2 = 0%) or cognitive
and behavioral therapy (MD: −3.80, 95% CI: −4.91 to −2.68, I2 = 68%) alone. There was no signiﬁcant dif-
ference between CHM and placebo regarding the frequency of adverse events (relative risk, RR: 1.65, 95%
CI: 0.67–4.10, I2 = 0). Overall, oral CHM used as a monotherapy or as an adjunct to conventional thera-
pies appears safe, and it may improve subjective sleep in people with insomnia. However, the typical
effect of CHM for insomnia cannot be determined due to heterogeneity. Further study focusing on indi-
vidual CHM formula for insomnia is needed. The development of a comparable placebo is also needed
to improve the successful blinding in RCTs.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Insomnia is a common sleep disorder. Around one-third of adults
experience the symptoms of insomnia, and approximately 6% meet
the diagnosis of insomniaworldwide [1]. Insomnia can result in func-
tional impairment as well as increase the risk of severe conditions
such as depression and cardiovascular disease in the long term [2,3].
Growing evidence suggests that cognitive behavioral therapy for in-
somnia (CBT-i) is effective in improving subjective sleep outcomes
[4]. However, it is underutilized in clinical practice because of dif-
ﬁculties in successful patient compliance [5] and high requirements
of well-trained psychotherapists [6]. Pharmacotherapy such as ben-
zodiazepine receptor agonists (BZRAs) is considered beneﬁcial in
improving sleep as well [7]. However, it is not without risks in-
cluding tolerance and addiction from long-term use [8,9]. Therefore,
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new treatments with low risk to beneﬁt ratio are needed for
insomnia.
Chinese herbal medicine (CHM), originating from ancient China,
has been used to treat insomnia for >2000 years in China [10]. In
modern China, both traditional herbal formulae and patent herbal
products coexist in the treatment of insomnia [11]. Furthermore,
conventional medicine and CHM are coadministered frequently in
clinical practice for sleep disorders [12–16]. In recent years, CHM
has been increasingly used as a form of complementary and alter-
native medicine (CAM) in the Western world such as in America,
Europe, and Australia [17]. Although the mechanism by which CHM
improves sleep is not fully elucidated, preclinical studies have shown
that some Chinese herbal formulae or single herbal ingredients have
sedative–hypnotic functions, which is mediated by the gamma-
aminobutyric acid-ergic (GABAergic) system [18]. For example, sour
jujube seed (scientiﬁc name: Ziziphus spinosa Hu; pharmaceutical
name: Semen Zizyphi Spinosae; and Chinese pinyin: suan zao ren)
has been shown to enhance the activity of GABA, an inhibitory neu-
rotransmitter, as a single herb [19] or as amain ingredient in amulti-
herb formulation (known as sour jujube seed decoction), which
modulates speciﬁc sedative effects by selective binding to the
GABA(A) receptors [20].
The public perception of the beneﬁt of CHM in improving overall
sleep and the potential hypnotic effects in animal studies need to
be supported through critical evaluation of the clinical evidence.
Two previous systematic reviews concluded that there was insuf-
ﬁcient evidence to support the eﬃcacy of CHM for insomnia [21,22].
However, the latest Chinese evidence-based guideline for insom-
nia acknowledges the importance of CHM [11] without speciﬁc data
on the role of CHM in clinical management for insomnia. Consid-
ering the growing number of clinical trials for CHM in recent years,
it is important to update the search and evaluation to provide the
best available evidence for insomnia. This systematic review and
meta-analysis of randomized controlled trials (RCTs) aims to answer
four clinical questions for insomnia: (1) whether CHM is more ef-
fective than placebo; (2) whether CHM is more effective than
conventional therapies such as BZRAs and psychotherapies; (3)
whether the adjunct use of CHM provides better outcomes than con-
ventional medicine alone; and (4) whether CHM is safe when used
alone or in combination with conventional therapies.
2. Methods
2.1. Eligibility
2.1.1. Inclusion criteria
2.1.1.1. Study designs. The RCTs were eligible.
2.1.1.2. Participants. Participants of any age, gender, or ethnic back-
ground with the main complaint of insomnia were included.
Insomnia needed to be deﬁned by standard diagnostic instru-
ments including International Classiﬁcation of Sleep Disorders (ISCD)
[23,24], Diagnostic and Statistical Manual of Mental Disorders (DSM)
[25], Chinese Classiﬁcation and Diagnosis of Mental Disease (CCMD)
[26], International Classiﬁcation of Diseases (ICD) [27], and other
current guidelines [12,13,28–30].
2.1.1.3. Interventions and controls. Intervention included oral CHM
treatment prepared in any form such as decoction, granule, capsule,
and tablet. Studies that evaluated CHM combined with conven-
tional therapies were also eligible. The comparators included placebo,
pharmacotherapy routinely used such as benzodiazepine drugs
(BZDs) and non-benzodiazepine drugs (non-BZDs), and psycho-
therapy such as CBT-i and sleep hygiene education. When another
treatment was combined with CHM, the adjunct needed to be the
same as the control.
2.1.1.4. Outcomes. The primary outcome was overall sleep quality
measured by the Pittsburgh Sleep Quality Index (PSQI). PSQI is a
well-validated and commonly used instrument for sleep quality as-
sessment. The global scores (value range: 0–21 points) were
calculated by its seven domains reported by patients, including sub-
jective sleep quality, sleep latency, sleep duration, habitual sleep
eﬃciency, sleep disturbances, use of sleepmedications, and daytime
dysfunction [31]. Higher scores indicated poorer sleep quality. It was
translated into 56 additional languages including Mandarin Chinese
[32]. In the Chinese population, its minimal clinically important dif-
ference (MCID) for Chinese medicine therapy was estimated to be
1.75 points by the standard error of measurement method or 1.54
by the distribution-based method [33]. Therefore, it was used as the
threshold to assess the generalization of results to clinical practice.
Secondary outcomes included the following: (1) the total scores
of the Athens Insomnia Scale (AIS) [34]; (2) the total scores of the
Insomnia Severity Index (ISI) [35]; (3) the patient-rated sleep pa-
rameters such as sleep-onset latency, total sleep duration, sleep
eﬃciency (ratio of time asleep to time on bed), and frequency of
early awakenings; (4) objective sleep parameters measured by
polysomnography (PSG), such as sleep-onset latency, total sleep du-
ration, sleep eﬃciency, and times or duration of awakening after
sleep onset; (5) clinical global impression (CGI) including the Clin-
ical Global Impression-Severity scale (CGI-S) and Clinical Global
Impression-Improvement scale (CGI-I) [36]; and (6) frequency and
nature of adverse events.
2.1.2. Exclusion criteria
• Quasi-randomized controlled trials
• Insomnia deﬁned as a symptom or a complaint only
• Insomnia induced by substances such as alcohol and drugs
• Participants with other sleep disorders, such as breathing-
related sleep disorders, restless leg syndrome, narcolepsy, delayed
sleep phase type of circadian rhythm sleep–wake disorders, and
parasomnias
• Participants diagnosed with other mental disease and physical
conditions
• Nonstandardized, but individualized, CHM and control for all
participants
• Another form of Chinese medicine therapy such as acupunc-
ture as control
• Pharmacotherapies not routinely recommended for insomnia,
such as antihistamine drugs, as control
• No relevant outcomes
2.2. Database search and study selection
Five English databases (Cochrane Library, PubMed, EMBASE,
CINAHL, and AMED), four Chinese databases (CBM, CNKI, CQVIP,
and Wanfang), and ﬁve clinical trial registration databases
(ClinicalTrials.gov, ICTRP, ChiCTR, EU-CTR, and ANZCTR) were com-
prehensively searched in May 2014. The search terms are speciﬁed
in the Appendix A.
Two researchers (XN and JS) searched and screened the studies
by ﬁnding duplications, excluding irrelevant titles and abstracts, and
then selecting eligible studies by reviewing full texts.
2.3. Data extraction and management
Two researchers (XN and FL) extracted data in the manner of
double entry and checking using EpiData Software, version 3.1
(EpiData Association, Odense, Denmark). Basic characteristics and
outcome data were extracted, including authors, year of publica-
tion, diagnostic instrument, disease duration, stage, sample size,
age, gender, details of intervention and control, information of
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follow-up, outcomes, and adverse events. The data were exported
from EpidData to Microsoft Excel 2010 to facilitate sorting. E-mails
were sent to the authors for clariﬁcation if important data were un-
available, duplication was suspected, or whenmore than one article
reported the same trial. Another researcher (JS) validated the ﬁnal
dataset and the translation into English.
2.4. Assessment of risk of bias in included studies
The risk of bias was appraised by two independent reviewers
(XN and LZ) according to the Cochrane Collaboration’s tool for as-
sessing the risk of bias [37]. Seven domains were evaluated, including
random sequence generation, allocation concealment, blinding of
participants and personnel, blinding of outcome assessment, in-
complete outcome data, selective reporting, and other bias. The
assessment for blinding was made based on patient-reported out-
comes (PROs) and clinician-reported outcomes (CROs). The objective
sleep parameters rated by PSGwere grouped as CROs because results
can be affected by the assessors and assessment environments. Study
protocols or registration information were used to help assess the
risk of bias for selective reporting. The risk of other bias was judged
by assessing baseline balance and funding source. Judgments were
categorized as “low risk of bias,” “high risk of biases,” or “unclear
risk of bias.” Disagreement was resolved by discussion and consul-
tation with a senior researcher (XG) when necessary.
2.5. Measures of treatment effect
Continuous outcomes were presented as mean difference (MD)
with 95% conﬁdence interval (CI) between two groups, whereas di-
chotomous data were presented as relative risk (RR) with 95% CI.
RevMan software (Version 5.2.4, Copenhagen: The Nordic Co-
chrane Centre, The Cochrane Collaboration, 2012) was used for data
analysis.
For trials with more than one CHM intervention group such as
CHM formula A versus CHM formula B versus pharmacotherapy, all
relevant CHM groups were combined; for trials with more than one
type of control such as CHM versus pharmacotherapy versus placebo,
pair-wise comparison results were reported based on different class
of comparators. When different outcomes for the same trial were
reported in separate publications, the data were merged into one
trial.
The predeﬁned main comparisons in the meta-analysis were as
follows: (1) CHM versus placebo, (2) CHM versus BZDs, (3) CHM
versus non-BZDs, (4) CHM versus psychotherapy, (5) CHM plus BZDs
versus placebo plus BZDs, (6) CHM plus non-BZDs versus placebo
plus non-BZDs, (7) CHM plus psychotherapy versus placebo plus psy-
chotherapy, (8) CHM plus BZDs versus BZDs, (9) CHM plus non-
BZDs versus non-BZDs, and (10) CHM plus psychotherapy versus
psychotherapy.
2.5.1. Subgroup analysis and solutions to heterogeneity
Clinical heterogeneity between trials for the primary outcome
was addressed by further subgroup analysis noting important factors
including treatment duration (≤4 weeks and >4 weeks), history of
insomnia (<1 year and ≥1 year), and different preparations of CHM
(decoction and non-decoction). Statistical heterogeneity was de-
tected using a chi-squared test. The ﬁxed-effect model was used to
estimate the typical effect for studies with low heterogeneity
(I2 < 50%), whereas the random-effects model was used to esti-
mate the average distribution for studies with substantial
unexplained heterogeneity (I2 ≥ 50%).
2.5.2. Sensitivity analysis
Blinding of participants and allocation concealment are impor-
tant for the PRO results. The primary outcome (PSQI) was a PRO,
and sensitivity analysis was performed by only including trials with
low risk of bias for blinding of participants and allocation
concealment.
In studies comparing CHM with pharmacotherapies, the sensi-
tivity analysis of PSQI scores was performed by including studies
that removed the sixth domain (use of medication) because par-
ticipants in the pharmacotherapy group would score higher on this
domain.
Imbalance baseline can suggest failure of randomization [38].
Another sensitivity analysis was conducted by excluding the studies
with the imbalance baseline of PSQI scores.
2.6. Publication bias
Publication bias was assessed when the subgroup included >10
studies.
3. Results
3.1. Description of included studies
3.1.1. Search results
The primary search identiﬁed 47,391 articles in literature data-
bases and seven records in registries. Seventy-nine RCTs with 7886
participants published in 81 articles were ﬁnally included in the sys-
tematic review [39–119]. A total of 76 were also included in the
meta-analyses [39–115,118]. The screening process is shown in Fig. 1.
3.1.2. Basic characteristics of the included studies
All included studies were randomized, parallel-group, con-
trolled trials conducted in China between 2003 and 2014. Sevenwere
multiarm studies [48,56,77,78,83,92,110], and the rest were two-
arm studies. The treatment duration ranged from one week to three
months (mean: 29 days, median: 29 days, mode: 28 days). Thir-
teen conducted follow-up ranging from oneweek to sixmonths after
the end of the treatment [43,45,63,65,80,81,87,89,100,101,
103,108,116,117]. Participants ranged in age from 15 to 84 years,
and insomnia was diagnosed by CCMD-3 in 64 studies
[39,40,42–48,50–56,58–71,73,74,77–80,82,84,85,87,89–92,94–96,
98–100,102,104–110,112–117,119], ICSD-2 in six studies
[41,76,93,97,103,111], ICD-10 in seven studies [49,57,72,75,81,
83,101,118], DSM-4 in one study [88], and Chinese national guide-
line in one study [86]. The duration of insomnia history ranged from
one month to 30 years. The PSQI was reported in 59 studies
[39–43,46–51,53–55,57,58,60–65,67,68,72–84,86–88,90–96,
98–104,106,108,109,111,114,119], the AIS in eight studies
[52,56,59,66,85,97,110,115], patient-rated sleep parameters in 13
studies [41,44,45,50,68,69,71,80,95,103,105,112], PSG-reported sleep
parameters in two studies [76,94], and the CGI-S in four studies
[70,89,107,113]. The ISI and the CGI-I were not reported in any study.
Twenty-six studies used Chinese patent herbal products
[41,48,54,58,60,64,67,71,74,75,80–83,91,93–96,99–101,103,104,108,
111,119], and other studies used decoctions, the traditional form,
and combination method. Sixty-six herbal formulae were investi-
gated in the included studies. The most frequent formulae were Xue
Fu Zhu YuTang (traditional decoction) and Zao Ren An Shen Capsule
(patent product). The herb most commonly used was sour jujube
seed. The complete characteristics of the included studies are shown
in Tables 1 and 2.
3.2. Risk of bias in the included studies
Only one study registered the protocol in ChiCTR [76]. The
risk of bias for other studies was assessed based on their
publications. Twenty-seven studies (34.18%) reported adequate
methods of random sequence generation, including computer
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software [68,76,80,81,95,101,104], random number table [40,43,48,
50,53,54,57,65,69,73,77,78,82–84,87,88,90,93,106,108], and
drawing of lots [111]. Sequence allocation was concealed in ﬁve
studies (6.33%) [68,75,80,81,95,101]. Blinding of participants and
personnel were performed in 10 studies (12.66%) [41,63,68,
76,80,81,94,95,101,104,108]. Only one study (1.27%) used an
independent outcome assessor [76]. Two studies (2.53%) had
high dropout rate with unreported reasons, and they did not
appropriately treat missing data [76,87]. One study (1.27%) did not
report its predeﬁned primary outcome (PSQI scores) with unre-
ported reason [112]. Three studies showed imbalance baseline
(3.80%) [50,82,109]. Sixteen studies (20.25%) were supported by
nonproﬁt institutions, such as by national scientiﬁc funding
[75,76,95] or local scientiﬁc grant [43,46–48,64,73,77,78,84,
85,87,93,111,115], and the rest did not declare the presence or
absence of a conﬂict of interest and the funding sources. The risk
of bias is summarized in Fig. 2.
3.3. Estimated effect of CHM on insomnia
3.3.1. Pittsburgh Sleep Quality Index
3.3.1.1. CHM alone versus control. In terms of sleep quality as-
sessed by PSQI, CHM was more effective than placebo (MD: −3.06,
95% CI: −5.14 to −0.98, I2 = 97%; n = eight RCTs, 853 participants)
[63,68,80,83,94–96,101] and BZDs (MD: −1.94, 95% CI: −2.45 to −1.43,
I2 = 96%; n = 35 RCTs, 3361 participants) [40,42,43,46–51,53–55,
57,60–62,64,67,72–75,82,83,86,87,90,93,98–100,102,103,106,114].
However, CHM was not superior to non-BZDs (MD: −0.16, 95% CI:
−0.65–0.33, I2 = 57%; n = three RCTs, 323 participants) [39,65,84] or
psychotherapy (MD: −1.23, 95% CI: −2.48–0.01, n = one RCT, 120 par-
ticipants) [92]. A four-arm, double-blind, double-dummy RCT (33
participants) reported that CHM plus placebo of BZDs was not su-
perior to BZDs plus placebo of CHM (MD: −2.10, 95% CI: −6.00–
1.80) or placebo of BZDs plus placebo of CHM (MD: −1.60, 95% CI:
−4.45–1.25) [76]. The results are shown in Fig. 3.
Fig. 1. Flowchart of study screening.
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Table 1
Basic characteristic of the included studies.
Study Arm Randomized
sample size: I/C
Age: mean (SD) years, I/C Gender: M/F Diagnostic
instrument
Duration of insomnia history:
mean (SD), I/C
Outcomes Follow-up
Niu ZZ 2014 [87] 2 48/48 41.32 (7.46) /40.12 (8.66) 38/58 CCMD-3 28.36 (11.51) m/26.89 (13.65)
m
PSQI 10 d
Li ZJ 2014 [79] 2 50/50 43.32 (11.31)/42.13 (12.41) 47/54 CCMD-3 28.36 (8.38) m/27.62 (7.68) m PSQI No
Cai TR 2013 [43] 2 98/49 46.2 (6.5)/47 (6.2) 56/91 CCMD-3 5.6 (1.2) y/5.9 (1) y PSQI 3 m
Hou N 2013 [60] 2 54/54 42.3 (5.3)/43.5 (4.3) NS CCMD-3 NS PSQI No
Wang SM 2013 [94] 2 48/48 45.12 (11.51)/44.58 (12.17) 34/62 CCMD-3 27.16 (35.05) m/25.99 (32.17)
m
PSQI and PSG No
A M 2013 [39] 2 41/41 44.45 (8.33)/45.12 (7.76) 55/27 CCMD-3 6.32 (2.43) y/6.76 (2.01) y PSQI No
Gan JG 2013 [54] 2 60/60 67.2 (5)/66.5 (9.2) 46/74 CCMD-3 19.4 (6.1) m/20.6 (8.7) m PSQI No
Zhang XZ 2013 [112] 2 110/55 40.5 (8.6)/41.3 (9.2) 65/100 CCMD-3 16.5 (2.7) m/15.5 (2.8) m Patient-rated sleep
parameters
No
Huang HB 2013 [63] 2 33/33 28 (2.14)/30 (2.21) 32/34 CCMD-3 1.6 (0.61) y/1.4 (0.47) y PSQI 30 d
Huang WM 2013 [97] 2 39/35 41.7 (10.5)/40.8 (9.8) 31/43 ICSD-2 19.2 (5.5) m/17.7 (4.7) m AIS No
Li GX 2013 [75] 2 35/35 49.93 (11.54)/52.7 (10.54) 27/34 WHO ICD-10 10.13 (13.42) y/11.94 (10.31) y PSQI No
Sun XA 2013 [91] 2 50/50 40.34 (12.6)/41.15 (12.7) 51/49 CCMD-3 2.64 (5.11) y/2.15 (4.18) y PSQI No
Yuan CX 2013 [108] 2 30/30 39.57 (12.38)/34.53 (11.73) 11/49 CCMD-3 2.18 (2.08) y/2.18 (1.98) y PSQI 7 d
Lin YY 2013 [82] 2 30/30 70.85 (3.06)/71.14 (3.24) 27/33 CCMD-3 6.43 (3.88) y/6.55 (3.12) y PSQI No
Han YC 2013 [57] 2 32/32 45.2 (19.3)/40.7 (16) 26/38 WHO ICD-10 7.8 (3.4) m/8.3 (3.9) m PSQI No
Pan BX 2013 [88] 2 40/40 40.25 (11.71)/41.25 (15.3) 36/44 DSM-4 3.30 (5.29) y/3.22 (4.14) y PSQI No
Qian C 2012 [41] 2 158/52 44.97 (13.55)/42.75 (13.81) 74/136 ICSD-2 108.32 (44.12) d/111.79 (44.96)
d
PSQI and patient-
rated sleep
parameters
No
Chen WM 2012b [46] 2 60/30 39.8 (12.77)/37.3 (12.39) 53/37 CCMD-3 28.2 (11.9) m/24.9 (12.3) m PSQI No
Zhang CL 2012 [51] 2 48/30 50/49 49/29 CCMD-3 1.9 y/1.8 y PSQI No
Sheng CJ 2012 [50] 2 25/21 56.1 (6.5)/57.3 (7.1) 18/28 CCMD-3 NS PSQI and patient-
rated sleep
parameters
No
Yang YL 2012 [117] 2 60/60 73.15 (10.19)/73.18 (10.15) 81/39 CCMD-3 4.97 (2.11) y/4.95 (2.15) y PSQI 6 m
Yang XC 2012 [99] 2 30/30 41 (12)/43 (13) 28/32 CCMD-3 7 m–1 y/6 m–21 y PSQI No
Chen WM 2012a [47] 2 50/30 38.95 (10.57)/38.35 (11.58) 43/37 CCMD-3 26.5 (10.8) m/25.9 (11.2) m PSQI No
Wang LH 2012 [93] 2 38/38 61 (12.4)/61 (12.8) 34/36 ICSD-2 NS PSQI No
Lou YY 2012 [109] 2 30/30 72.83 (6.18)/74.1 (7.33) 31/29 CCMD-3 4.13 (2.11) y/5.34 (4.2) y PSQI No
Li Y 2012 & Li Y 2013 [77,78] 3 30/30/30 NS NS CCMD-3 NS PSQI No
Li GR 2012 [74] 2 30/30 37.8/37.4 28/32 CCMD-3 NS PSQI No
Zhang HM 2012 [59] 2 32/34 34.32 (1.45)/32.34 (1.67) 27/39 CCMD-3 7.34 (0.65) m/9.13 (0.15) m AIS No
Li XL 2012 [102] 2 96/90 43 (2)/43.5 (1) 73/113 CCMD-3 1.5 (0.5) y/1.8 (0.2) y PSQI No
Miao WH 2012 [96] 2 30/29 44.46 (12.34)/43.51 (12.81) 18/41 CCMD-3 24.70 (29.74) m/17.48 (15.63)
m
PSQI No
Kuang JG 2012 [69] 2 40/40 73.8/74.1 43/37 CCMD-3 3.7 y/4.1 y Patient-rated sleep
parameters
No
Li DY 2012 [73] 2 52/52 45.9 (11.3)/44.54 (10.6) 41/63 CCMD-3 9.3 (4.7) m/10.7 (5.3) m PSQI No
Luo HO 2012 [84] 2 60/59 NS 46/71 CCMD-3 NS PSQI No
Zhu GQ 2012 [114] 2 34/34 NS 32/36 CCMD-3 NS PSQI No
Cai Y 2011 [44] 2 21/21 40.17 (11.26)/41.36 (11.48) 19/23 CCMD-3 15.92 (11.55) m/16.39 (12.21)
m
Patient-rated sleep
parameters
No
Qi GF 2011 [55] 2 40/40 51.2 (10.3)/53.5 (12.42) 36/44 CCMD-3 5.62 (2.35) y/6.30 (3.12) y PSQI No
Sun P 2011 [90] 2 40/40 66.7 (5.8)/67.1 (6.2) 25/55 CCMD-3 12.8 (6.4) m/13.28 (6.9) m PSQI No
Zhu WH 2011 [115] 2 31/30 NS 20/40 CCMD-3 NS AIS No
Huang XY 2011 [64] 2 50/50 44.58 (10.25)/44.2 (7.83) 40/60 CCMD-3 5.3 (1.5) y/5.1 (1.8) y PSQI No
Jia B 2011 [40] 2 39/39 50.63 (10.56)/47.76 (10.58) 37/41 CCMD-3 18 m/16 m PSQI No
Wang C 2011 [42] 2 60/60 39.3/37.6 54/66 CCMD-3 2.9 y/3.1 y PSQI No
Yang XH 2011 [105] 2 50/50 46.1/45 50/50 CCMD-3 9.78 m/9.44 m Patient-rated sleep
parameters
No
Jing XW 2011 [104] 2 21/27 41.82 (12.88)/42.37 (11.64) 12/35 CCMD-3 7.9 (3.84) y/5.7 (2.53) y PSQI No
(continued on next page)
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Study Arm Randomized
sample size: I/C
Age: mean (SD) years, I/C Gender: M/F Diagnostic
instrument
Duration of insomnia history:
mean (SD), I/C
Outcomes Follow-up
Chen YY 2011 [49] 2 32/20 46.6 (1.5)/59.2 (0.9) 20/32 WHO ICD-10 3.2 (0.3) y/3.3 (0.4) y PSQI No
Xiao LG 2010 [72] 2 33/32 68.2 (18.3)/67.5 (19) 38/27 WHO ICD-10 38 (18.5) m/45 (16.2) m PSQI No
Jiang HQ 2010 [61] 2 183/183 71.9/70.8 176/188 CCMD-3 33.1(5.7) m/31.4 (7.1) m PSQI No
Wang ZT 2010 [95] 2 41/39 NS NS CCMD-3 NS Patient-rated sleep
parameters
No
Liao RD 2010 [116] 2 22/18 48.95 (1.468)/50.6 (1.911) 31/9 CCMD-3 NS PSQI 3m
Huang D 2010 [62] 2 42/38 50.2 (9.2)/53.6 (8.7) 47/33 CCMD-3 9.56 (5.42) y/10.37 (6.63) y PSQI No
Wang F 2010 [53] 2 59/60 40.23 (10.79)/39.92 (11.47) 36/83 CCMD-3 37.49 (7.36) m/35.81 (9.92) m PSQI No
Tian J 2010 [66] 2 30/30 70 (7)/67 (5) 26/34 CCMD-3 NS AIS No
Huang Y 2010 [65] 2 62/62 47 (9)/48 (10) 60/64 CCMD-3 4.8 (1.2) y/4.16 (1.6) y PSQI 4w
Song XH 2010 [81,101] 2 106/106 NS 54/147 WHO ICD-10 NS CGI-S 2w
Lian FM 2009 [80] 2 71/36 43.14 (13.91)/44.73 (13.92) 39/68 CCMD-3 19.83 (27.13) m/20.92 (45.12)
m
Patient-rated sleep
parameters
1w
Xia CY 2009 [52] 2 60/60 42.18 (9.82)/42.75 (10.72) 33/87 CCMD-3 11.09 (14.27) m/11.84 (14.29)
m
AIS No
Zhang XP 2009 [111] 2 82/80 71.14 (3.24)/70.85 (3.07) 89/73 ICSD-2 6.51 (3.27) y/6.02 (3.45) y PSQI No
Xu HK 2009 [58] 2 42/40 56 (7)/58 (7) 36/46 CCMD-3 56 (7) m/92 (8) m PSQI No
Nie ZH 2009 [86] 2 50/45 37.81(10.42)/41.24 (9.14) 39/53 Chinese
guideline
NS PSQI No
She YQ 2009 [106] 2 60/59 36.68 (8.53)/35.32 (9.13) 0/119 CCMD-3 3.22 (3.37) y/3.51 (3.67) y PSQI No
Li X 2008 [98] 2 68/52 36.64 (4.51)/37.26 (4.79) 60/60 CCMD-3 9 (4.85) m/8.89 (4.52) m PSQI No
Jiang LP 2008 [70] 2 34/34 44.8 (14.1)/39.26 (12.38) 31/37 CCMD-3 6.27 (4.18) m/5.91 (4.31) m CGI-S No
Feng XD 2008 [100] 2 25/23 NS 20/28 CCMD-3 NS PSQI Unclear
Zhang XM 2008 [103] 2 43/41 NS 38/46 ICSD-2 NS PSQI and patient-
rated sleep
parameters
3m
Zhang JP 2008 [71] 2 30/30 41.26 (10.25)/40.3 (13.62) 36/24 CCMD-3 2.35 (5.22) y/2.25 (4.27) y PSQI and patient-
rated sleep
parameters
No
Sun Y 2008 [118] 2 52/50 3836 44/58 WHO ICD-10 1.56 (1.04) y/1.61 (1.03) y PSQI No
Ren YJ 2007 [89] 2 50/50 NS 48/62 CCMD-3 NS CGI-S 7d
Chang C 2006 [119] 2 19/18 18-65 12/25 CCMD-3 51.32 (73.32) m/60.14 (92.3) m PSQI No
Chen JF 2006 [67] 2 30/30 NS 28/32 CCMD-3 NS PSQI No
Zheng SY 2006 [113] 2 34/34 38.67 (15.42)/39.26 (12.38) 28/40 CCMD-3 6.27 (4.18) m/5.92 (4.33) m CGI-S No
Luo LC 2006 [85] 2 52/30 51.2/50.5 32/50 CCMD-3 2.6 y/2.5 y AIS No
Chen FQ 2005 [45] 2 180/90 42 (15.4)/41 (14.9) 100/170 CCMD-3 NS Patient-rated sleep
parameters
3m
Yu HT 2005 [107] 2 48/45 32.6 (8.9)/30.6 (8.4) 45/48 CCMD-3 2.2 (0.6) y/2.8 (4.6) y CGI-S No
Zhang JF 2003 [68] 2 113/114 44.09 (13.29)/44.97 (13.11) 68/159 CCMD-3 79.64 (102.66) m/71.89 (93.5)
m
PSQI and patient-
rated sleep
parameters
No
Zhu T 2013 [92] 3 60/60/60 NS 71/109 CCMD-3 NS PSQI No
Chen H 2012 [56] 3 30/30/30 NS 75/15 CCMD-3 NS AIS No
Liu Y 2009 [83] 3 30/30/30 36.9 (11.48)/37.2 (11.36)/
37.8 (11.38)
38/52 WHO ICD-10 8.9 (2.89) m/9.3 (2.18) m/9.8
(2.28) m
PSQI No
Chen WQ 2008 [48] 3 68/72/76 62.19 (6.09)/64.32 (6.71)/
66.19 (5.81)
108/108 CCMD-3 NS PSQI No
Zhan SQ 2008 [110] 3 39/21/40 43.8 (12.8)/47.1 (10.8)/44.6
(14.4)
35/65 CCMD-3 NS AIS No
Li Y 2009 [76] 4 NS 32.7 (9.2)/37.6 (10.3)/38.4
(13.8)/30 (9.7)
8/25 ICSD-2 56.1 (36.4) d/39 (37.7) d/51.1
(32.9) d/ 47.7 (33.2) d
PSQI and PSG No
Abbreviations: AIS: Athens Insomnia Scale; BZDs: benzodiazepine drugs; C: control; CBT-i: Cognitive and behavioral therapy for insomnia; CHM: Chinese herbal medicine; CGI-S: Clinician Global Impression-Severity; CCMD-3:
Chinese Classiﬁcation and Diagnosis of Mental Disease, Third Edition; CGDTAI: Chinese Guideline on Diagnosis and Treatment for Adult Insomnia; DSM-4: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition;
d: day/days; F: female; M: male; m: month/months; I: intervention; ISCD-2: International Classiﬁcation of Sleep Disorders, Second Edition; NS: not stated; PSQI: Pittsburgh Sleep Quality Index; PSG: polysomnography; WHO
ICD-10: World Health Organization International Classiﬁcation of Diseases, 10th Version; w: week/weeks; y: year/years.
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Details of the treatment in the included studies.
Study Formula dHerbal ingredients cIM Preparation Dosage Frequency Comparator Treatment
duration
Niu ZZ 2014 [87] Bu Shen Shu Gan Tang shu di, gou qi zi,sheng di, xuan shen, mai dong, dang gui,
chuan xiong, chai hu, zhi ke, huang qin, huang lian, gan cao,
ye jiao teng, bai he, zhen zhu mu
N decoction 1 pack decocted
twice
bid clonazepam tablet,
2–4 mg, qn
30 d
Li ZJ 2014 [79] Jia Wei Chang Pu Yu Jin
Tang
shi chang pu, yu jin, huang lian, rou gui, yun fu shen, yuan
zhi,bai zi ren
Y decoction 1 pack decocted 3
times
tid estazolam tablet,
2 mg, qn
30 d
Cai TR 2013 [43] Tiao Zhong Hua Tan An
Shen He Ji
suan zao ren, fu ling, chai hu, huang qin, zhi mu, fa ban xia,
chuan xiong, chen pi, zhu ru, shou wu teng, zhen zhu mu, zhi
shi,zhi gan cao
N decoction 1 pack decocted
twice
bid estazolam tablet,
1–2 mg qn
2 w
Hou N 2013 [60] Mian An Ning Ke Li dan shen, shu di huang, shou wu teng, bai zhu, chen pi, yuan
zhi,da zao
N granule 1 bag bid alprazolam tablet
,0.4 mg qn
3 w
Wang SM 2013 [94] Zao Ren An Shen Pian he shou wu, suan zao ren, sang shen,he huan hua, bai zi ren,
dang gui, shu di huang, yuan zhi,chai hu
N tablet 4 tablets tid Placebo 4 w
A M 2013 [39] Zi Ni Yang Xin An Shen
Tang
sheng di huang ,mai men dong, dang gui, dan shen, ren shen,
fu shen, bai zi ren, suan zao ren,ye jiao teng,zhi gan cao
N decoction 1 pack decocted 3
times
tid zolpidem tablet,
5 mg, qn
4 w
Gan JG 2013 [54] Zao Ren An Shen Jiao
Nang
suan zao ren, dan shen,wu wei zi N capsule 5 tablets qn alprazolam tablet
,0.8 mg, qn
4 w
Zhang XZ 2013 [112] Yang Yin An Shen Jiao
Nang
suan zao ren, wu wei zi, ye jiao teng, zhi mu, fu shen, he huan
hua, dan shen, hu po,ling ci shi
N capsule 3 mg bid alprazolam tablet,
0.4–0.8 mg, qn
4 w
Huang HB 2013 [63] Xie Cao xie cao N powder 3 g tid Placebo 150d
Huang WM 2013 [97] Wen Dan Tang plus
Xue Fu Zhu Yu Tang Jia
Jian
fa ban xia, chen pi, zhu ru, zhi shi, fu ling, tao ren, hong hua,
chi shao, chuan xiong, niu xi, sheng di huang,dang gui, ,jie
geng,gan cao
N decoction 1 pack decocted
twice
bid estazolam tablet,
2 mg, qn
30 d
Li GX 2013 [75] Wen Dan Ning Xin Ke
Li
suan zao ren, dang shen, ban xia, chen pi, zhu ru, zhi shi, fu
ling,shi chang pu, yuan zhi, shu di huang, long gu, mu li,zhi
gan cao
N granule 6 g tid estazolam tablet,
1–2 mg, qn
4 w
Sun XA 2013 [91] Shui Mian Ling ren shen, huang qi, wu wei zi, bai he, zhi yu cao,chao suan
zao ren, ye jiao teng, dan shen, yuan zhi,fu ling, sheng di,nv
zhen zi, chai hu, yu jin, he huan pi, shen qu, shan zha, you
dong, bai zhu, zhi ke,ban xia
Y pill 10 g tid zopiclone tablet,
3.75 mg qn
4 w
Yuan CX 2013 [108] Mei An Ke Li suan zao ren ,ren shen ,ci wu jia ,fu ling ,dang gui ,chuan
xiong
Y granule 4.0 g qn placebo + estazolam,
1 mg, qn
2 w
Lin YY 2013 [82] Jian Nao Ning Shen Ke
Li
suan zao ren ,bai zi ren ,huang lian ,zhi zi ,bai shao ,mai dong
,dan shen ,long gu ,zhen zhu mu ,yuan zhi ,bai he ,shou wu
teng
N granule 1 bag bid estazolam tablet,
1 mg, qn
4 w
Han YC 2013 [57] Tian Wang Bu Xin Dan bai shao ,dan shen ,chao zao ren ,bai zi ren ,bai he ,shou wu
teng ,chao bai zhu ,fu ling ,sha ren ,ji nei jin ,zhen zhu mu
,duan long chi ,rou gui ,bai dou kou ,zhi gan cao ,zhi zi
N decoction 1 pack decocted 4
times
qid alprazolam tablet
,0.4–0.8 mg,qn
4 w
Pan BX 2013 [88] Jian Pi Shu Gan Tang
plus Fu Fang Zao Ren
Jiao Nang
tang ji :dang shen ,fu chao bai zhu ,fu ling ,chen pi ,fa ban xia
,chao chai hu ,bai shao ,dang gui ,bo he ,yi yi ren ,shan yao
,zhi yuan zhi ,shou wu ,shen qu ,sha ren ,chao gu ya ,gan cao
Y Decoction + capsule 1 bag decocted
twice;0.4g
bid; qn estazolam tablet,
0.5–1 mg, qn
2 w
Qian C 2012 [41] Nan WuWei Zi Jiao
Nang
nan wu wei zi Y capsule 2 capsules qn Placebo 4 w
Chen WM 2012b [46] Tian Wang Bu Xin Dan suan zao ren ,bai zi ren ,dang gui ,tian men dong ,mai men
dong ,sheng di huang ,dang shen ,dan shen ,xuan shen ,fu ling
,wu wei zi ,yuan zhi ,ju geng
N decoction 1 pack decocted
twice
bid estazolam tablet,
1 mg qn
8 w
Zhang CL 2012 [51] Zi Ni Yi Shen An Mei
Tang
shu di huang ,yin yang huo ,huang jing ,nv zhen zi ,wu wei zi
,bai shao ,suan zao ren ,sheng long gu,sheng mu li ,fo shou
,gan song
N decoction 1 pack decocted
twice
bid diazepam tablet,
5 mg qn
1 m
(continued on next page)
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Sheng CJ 2012 [50] Jian Pi He Wei Zhong
Yao
yi yi ren ,huai shan yao ,fu ling ,ze xie ,zhu ling ,chen pi ,jiao
san xian ,pu gong ying ,suan zao ren ,gan cao
N decoction NS NS diazepam tablet,
5–10 mg, qn
10 d
Yang YL 2012 [117] Suan Zao Ren Shui suan zao ren N decoction 1 pack decocted
once
qn benzodiazepine
drugs without
details
1 w
Yang XC 2012 [99] Jie Yu Wan zi shao ,chai hu ,dang gui ,fu ling ,gan cao ,xiao mai ,da zao
,yu jin ,he huan pi
N pill 4 g bid estazolam tablet,
1–2 mg, qn
4 w
Chen WM 2012a [47] Gui Pi Tang huang qi ,dang shen ,bai zhu ,dang gui ,fu shen ,suan zao ren
,yuan zhi ,mu xiang ,gan cao ,long yan rou
N decoction 1 pack decocted
twice
bid estazolam tablet,
1 mg, qn
8 w
Wang LH 2012 [93] Er Dong Yang Xin Kou
Fu Ye
di huang,tian dong,mai dong,huang qi,dang shen,bai zhu N oral solution 20 ml bid estazolam tablet,
1 mg qn
4 w
Lou YY 2012 [109] Wen Yang Huo Xue
Ning Xin Fang
dang gui ,zhi fu pian ,tao ren ,hong hua ,chuan xiong ,gua lou
ke ,chi shao ,sheng di ,shi chang pu ,jiu yuan zhi ,suan zao ren
,ye jiao teng ,zhen zhu mu
Y decoction 1 pack decocted
once
qd estazolam tablet,
1 mg, qn
4 w
Li Y 2012 & Li Y 2013
[77,78]
1.Qing Zhen Tang; 2.Jia
Wei Wen Dan Tang
1. huang lian ,sha shen ,bai he ,dan shen ,yuan zhi ,niu xi ,shi
ju pu ,gan cao ,rou gui ,fu ling ,zhu ru ,yan huang bai ,long gu
,mu li, zhu ye,ge gen ,yu jin; 2. chen pi ,fa ban xia ,fu ling ,zhi
shi ,zhu ru ,shi chang pu ,dan nan xing ,zhi mu ,yuan zhi ,zhen
zhu mu ,ye jiao teng ,chuan xiong ,bai he ,chao zao ren ,gan
cao
Y decoction 1 pack decocted
once
qd CBT 8 w
Li GR 2012 [74] Zao Ren An Shen Jiao
Nang
chao suan zao ren ,dan shen ,cu zhi wu wei zi N capsule 5 capsules estazolam tablet,
1 mg, qn
2 w
Zhang HM 2012 [59] Xue Fu Zhu Yu Tang chai hu ,zhi ke ,chi shao ,tao ren ,chuan hong hua ,dang gui
,chuan xiong ,sheng di ,niu xi ,ju geng
N decoction 1 pack decocted 3
times
tid estazolam tablet,
1 mg, qn
4 w
Li XL 2012 [102] Xue Fu Zhu Yu Tang tao ren ,hong hua ,dang gui ,sheng di huang ,chuan xiong ,chi
shao ,niu xi ,ju geng ,chai hu ,zhi ke ,gan cao
N decoction 1 pack decocted
twice
bid estazolam tablet,
1 mg, qn
4 w
Miao WH 2012 [96] Xin Ren Shen An Jiao
Nang
sheng di huang,suan zao ren,lian zi xin,yuan zhi,chen pi,gan
cao
N capsule 1.35 g tid Placebo 4 w
Kuang JG 2012 [69] Tian Ma Gou Teng Yin tian ma ,gou teng ,shi jue ming ,du zhong ,niu xi ,shan zhi
,huang qin ,ye jiao teng ,fu shen
N decoction 1 pack decocted
twice
bid diazepam tablet,
2.5 mg, qn
4 w
Li DY 2012 [73] He Wei An Shen Fang ban xia ,yi yi ren ,shi chang pu ,fu ling ,bai zhu ,he huan pi ,ye
jiao teng ,chao zao ren ,
N decoction 1 pack decocted
twice
bid estazolam tablet,
1 mg, qn
4 w
Luo HO 2012 [84] He Wei An Shen Fang ban xia ,sheng yi ren ,chen pi ,fu ling ,bai zhu ,chai hu ,chao
huang qin ,ye jiao teng ,zhi gan cao
N decoction 1 pack decocted
twice
bid zolpidem tablet,
10 mg, qn
4 w
Zhu GQ 2012 [114] Gan Cao Xie Xin Tang gan cao ,dang shen ,huang qin ,huang lian ,gan jiang ,ban xia
,da zao
N decoction 1 pack decocted
twice
bid alprazolam tablet
,0.4–0.8 mg, qn
12 w
Cai Y 2011 [44] Zi Ni Shu Gan Qing Xin
Tang
chai hu ,yu jin ,fo shou ,zhi zi ,he huan pi ,ye jiao teng ,suan
zao ren ,bai shao ,chuan lian zi ,fu shen ,an mu xiang ,zhi mu
,gan cao
N decoction 1 pack decocted
twice
bid diazepam tablet,
2.5–5.0 mg, qn
2 w
Qi GF 2011 [55] Zi Ni Qing Hua Zi Yin
Fang
ban xia ,xia ku cao ,jiang can ,yu jin ,huang lian ,bai he ,zhi
mu ,fu ling ,yuan zhi ,chao zao ren ,sheng di huang ,dang gui
,dan shen ,ye jiao teng ,sheng long chi
N decoction 1 pack decocted
twice
bid estazolam tablet,
1 mg, qn
28 d
Sun P 2011 [90] Zi Ni Jie Yu Hua Tan An
Shen Tang
huang lian ,dan nan xing ,chai hu ,bai shao ,zhi ke ,xiang fu
,zhu ru ,ban xia ,chang pu ,yu jin ,fu ling ,ye jiao teng ,yuan
zhi ,sheng gan cao
N decoction 1 pack decocted
twice
bid estazolam tablet,
2 mg, qn
30 d
Zhu WH 2011 [115] Wu Ling Jiao plus Nang
Zao Ren An Shen Jiao
Nang
wu ling jun N capsule 3capsules tid, qn estazolam tablet,
1 mg, qn
30 d
Huang XY 2011 [64] Wu Ling Jiao Nang wu ling jun N capsule 3 capsules tid diazepam tablet,
5 mg, qn
4 w
(continued on next page)
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Jia B 2011 [40] Wen Bu Zhen She Fang zhi fu zi ,rou gui ,yin yang huo ,ling ci shi ,long chi ,zhen zhu
mu ,wu wei zi ,chang pu ,yuan zhi ,zhi gan cao
N decoction 1 pack decocted
twice
bid diazepam tablet,
5 mg, qn
30 d
Wang C 2011 [42] Qing Xin Ning Shen
Fang
lian zi xin ,jiu huang lian ,shui niu jiao ,lian qiao ,shan zhi
,zhu ye ,wu wei zi ,mai dong ,yuan zhi ,chang pu ,yu jin ,suan
zao ren ,bai zi ren
N decoction 1 pack decocted
twice
bid estazolam tablet,
1 mg, qn
4 w
Yang XH 2011 [105] Gui Pi Tang huang qi ,fu ling ,bai zhu ,dang shen ,suan zao ren ,mu xiang
,yuan zhi ,zhi gan cao ,long yan rou ,dang gui ,bai zi ren ,ye
jiao teng ,he huan pi
N decoction 1 pack decocted 3
times
tid estazolam tablet,
1 mg, qn
4 w
Jing XW 2011 [104] Xin Shen Ning Pian suan zao ren ,fu ling ,shou wu teng ,shen qu ,wei zi Y tablet 6 tablets tid placebo + estazolam
tablet, 1 mg, qn
3 w
Chen YY 2011 [49] Chai Hu Jia Long Mu
Tang plus Ban Xia Xie
Xin Tang
chai hu ,huang qin ,huang lian ,ban xia ,dang shen ,gui zhi
,bai shao ,gan jiang ,sheng long gu ,sheng mu li ,ye jiao teng
,gan cao ,da zao
N decoction 1 pack decocted
twice
bid estazolam tablet,
2 mg, qn
8 w
Xiao LG 2010 [72] Bu Xin An Shen Hua
Tan Fang
shu di huang ,bai shao yao ,e jiao ,suan zao ren ,fu shen ,bai zi
ren ,chen pi ,fa ban xia ,zhu ru ,he huan pi
N decoction 1 pack decocted
twice
bid estazolam tablet,
1.3 mg, qn
6 w
Jiang HQ 2010 [61] Fu Zha Zao Ren Tang fu ling ,shan zha ,suan zao ren N decoction 1 pack decocted
twice
bid alprazolam tablet ,
0.4–0.8 mg, qn
3 w
Wang ZT 2010 [95] San Qi Ke Li suan zao ren ,ji xue teng ,san qi ,xiao ji N granule 1 bag qd Placebo 4 w
Liao RD 2010 [116] No Name Formula sang ye ,ju hua ,tian ma ,gou teng ,chai hu ,long gu ,mu li ,yu
jin ,shi chang pu ,chi bai shao ,dan shen ,he huan pi
N decoction 1 pack decocted
once
qd estazolam tablet,
1–2 mg, qn
2 w
Huang D 2010 [62] Xue Fu Zhu Yu Tang tao ren ,hong hua ,dang gui ,chuan xiong ,sheng di huang ,chi
shao ,chai hu ,zhi ke ,niu xi ,ju geng ,gan cao
N decoction 1 pack decocted
twice
bid alprazolam tablet,
0.8 mg, qn
4 w
Wang F 2010 [53] Jie Yu Ning Shen Fang chai hu ,yu jin ,bai zi ren ,dang shen ,bai zhu ,shan yao ,suan
zao ren ,shan yu rou ,yuan zhi ,fu shen ,bai he ,sheng long mu
,zhen zhu mu ,hu po ,tao ren
N decoction 1 pack decocted
twice
bid diazepam tablet,
5 mg qn
28 d
Tian J 2010 [66] Shen Qi WuWei Zi
Pian
wu wei zi ,dang shen ,huang qi ,suan zao ren N tablet 3 tablets tid estazolam tablet,
1 mg, qn
8 w
Huang Y 2010 [65] An Shen Gao lian zi ,qian shi ,fu ling ,hei zhi ma ,mi zao ren ,bai zi ren ,ye
jiao teng ,yuan zhi ,e jiao
N soft extracts 15 ml qn zopiclone tablet,
7.5 mg, qn
6 w
Song XH 2010
[81,101]
Wu Ling Jiao Nang wu ling jun N capsule 0.99 g tid Placebo 4 w
Lian FM 2009 [80] Chan Ye An Shen Jiao
Nang
tian zhu huang ,can tui ,shou wu teng ,jiang can ,di long ,bai
shao ,gou teng ,fa ban xia ,suan zao ren ,yuan zhi
N capsule 2 g qd Placebo 3 w
Xia CY 2009 [52] Xia’s No.1 Sleep
Prescription
huang qi, bai zhu, suan zao ren,ye jiao teng, he huang pi, dan
shen, huai xiao mai, fu ling, zhi yuan zhi, long gu, e jiao
N decoction 1 pack decocted
twice
bid Estazolam, 1 mg,
qn
6 w
Zhang XP 2009 [111] Shen Song Yang Xin
Jiao Nang
ren shen ,mai dong ,wu wei zi ,sang ji sheng, shan zhu
yu,suan zao ren ,dan shen ,chi shao ,tu bie chong ,gan song
,huang lian ,long gu
Y capsule 1.6g qn to tid CBT 12w
Xu HK 2009 [58] Yin Dan Xin Nao Tong
Ruan Jiao Nang
yin xing ye ,deng zhan xi xin ,dan shen ,jiao gu lan ,san qi
,bing pian ,shan zha ,da suan
Y capsule 0.8g bid estazolam tablet,
2 mg, qn
4 w
Nie ZH 2009 [86] Rou Gan Ning Shen
Tang
suan zao ren ,long chi ,bai shao ,ye jiao teng ,he huan pi ,yu
jin ,dan pi ,chao zhi zi ,gua lou pi ,fu ling ,
N decoction 1 pack decocted
twice
bid alprazolam tablet,
0.4–0.8 mg, qn
2 w
She YQ 2009 [106] No Name Formula suan zao ren ,chuan xiong ,fu ling ,zhi mu ,gan cao N decoction 1 pack decocted
twice
bid diazepam tablet,
5 mg, qn
4 w
Li X 2008 [98] Zhu Mian Tang ye jiao teng ,chao zao ren ,wu wei zi ,lian zi rou ,bai zi ren ,shi
chang pu ,yuan zhi ,fu ling ,zhi mu ,zhu ru ,ban xia ,gan cao
N decoction 1 pack decocted
twice
bid alprazolam tablet ,
0.4–0.8 mg, qn
20 d
Jiang LP 2008 [70] Jie Yu Wan bai shao ,chai hu ,dang gui ,yu jin ,fu ling ,bai he ,he huan pi
,gan cao ,xiao mai ,da zao ,
N pill 12 g tid estazolam tablet,
2–12 mg, bid
6 w
Feng XD 2008 [100] Wu Ling Jiao Nang wu ling jun N capsule 3 capsules tid alprazolam tablet,
0.4–0.8 mg, qn
60 d
(continued on next page)
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Zhang XM 2008
[103]
An Shen Jiao Nang suan zao ren ,zhi mu ,dan shen ,fu ling ,chuan xiong ,mai
dong ,zhi shou wu ,wu wei zi
N capsule 4 capsules tid alprazolam tablet,
0.4–0.8 mg, qn
8 w
Zhang JP 2008 [71] Ye He Jian Nao Pian ye jiao xi ,he huan pi ,wu wei zi ,yuan zhi Y tablet 5 capsules tid zopiclone tablet,
7.5 mg, qn
4 w
Sun Y 2008 [118] Zi Ni Wu Hua Shu Gan
Tang
fo shou hua ,dai dai hua ,lv e mei ,chuan piao hua ,mei gui
hua ,shou di ,dang gui ,bai shao ,chao bai zhu ,zhi gan cao
N decoction 1 pack decocted
twice
bid alprazolam tablet,
0.4–0.8 mg, qn
4 w
Ren YJ 2007 [89] Zao Ren An Shen Jiao
Nang
suan zao ren ,dan shen ,wu wei zi N capsule 5 capsules qn estazolam tablet,
1 mg, qn
16 d
Chang C 2006 [119] Xin Ren Shen An Jiao
Nang
sheng di huang ,suan zao ren ,lian zi xin ,yuan zhi ,chen pi
,gan cao
Y capsule 3 capsules tid Placebo + sleep
hygiene education
4 w
Chen JF 2006 [67] Tian Meng Jiao Nang huang jing ,huang qi ,dang shen ,ci wu jia ,yin yang huo (zhi
),shan yao ,ze xie ,fu ling ,gou qi zi ,shu di huang ,ma qian zi
(zhi )
N capsule 3 capsules bid alprazolam tablet,
0.4–0.8 mg, qn
1 m
Zheng SY 2006 [113] Bai Lian Tang bai he ,lian zi xin ,chao zao ren ,shan yu rou ,sheng mu li ,fu
shen ,mai dong ,wu wei zi ,shi chang pu ,chuan bei mu ,he
huan pi
N decoction 1 pack decocted
twice
bid estazolam tablet,
2–12 mg, bid
6 w
Luo LC 2006 [85] Yi Shen Qiang Shen Yin rou cong rong ,huang jing ,huang qi ,shan zha ,jue ming zi N granule 4.5g qd diazepam tablet,
5 mg, qn
1 m
Chen FQ 2005 [45] An Shui Chong Ji chai hu ,dang gui ,xia ku cao ,gou teng ,dan shen ,sheng di
,long yan rou ,bai he ,zhen zhu mu ,ye jiao teng
N granule 9–18 g tid diazepam tablet,
2.5–5.0 mg, qn
1 m
Yu HT 2005 [107] Jia Wei Suan Zao Ren
Tang
suan zao ren ,zhi mu ,chuan xiong ,fu ling ,long gu ,chi shao
,wu wei zi ,yuan zhi ,gan cao
Y decoction 1 pack decocted
once
qd lorazepam tablet,
0.5–1.5 mg, qn
4 w
Zhang JF 2003 [68] Suan Zao Ren Gao suan zao ren ,zhi mu ,fu ling ,chuan xiong N soft extracts 20 g bid Placebo 4 w
Zhu T 2013 [92] Yang Xin An Shen Tang bai zi ren ,ye jiao teng ,he huan pi hua,fu shen ,chao zao ren
,dang gui ,bai shao ,hu po mo ,wu wei zi ,chen pi ,zhi ke
N + Y decoction 1 pack decocted
twice
bid CBT 4 w
Chen H 2012 [56] Bai Le Mian Jiao Nang bai he ,ci wu jia ,shou wu teng ,suan zao ren ,he huan hua
,zhen zhu mu ,shi gao ,fu ling ,yuan zhi ,dang can ,sheng di
huang ,mai dong ,wu wei zi ,deng xin cao ,dan can
N + Y capsule 4 capsules bid zolpidem, 10 mg,
qn
8 w
Liu Y 2009 [83] Zao Ren An Shen Jiao
Nang
zao ren ,dan can ,wu mei zi N capsule 5 capsules qn a1: estazolam
tablet, 1 mg, qn; 2:
placebo, 5 capsule,
bid
3 w
Chen WQ 2008 [48] Nao Kang II zhi shou wu ,shou di ,san qi ,chang pu N + Y oral solution 50 ml bid diazepam tablet,
2.5 mg, qn
4 w
Zhan SQ 2008 [110] Huo Li Su Kou Fu Ye zhi shou nia ,gou qi zi ,zhi huang jing ,huang qi ,yin yang huo
,dan can
N + Y oral solution 10 ml bid zolpidem,
5–10 mg, qn
4 w
Li Y 2009 [76] Jia Wei Xiao Yao San suan zao ren, fu shen, chai hu, dang gui,bai shao, bai shu, gan
cao,bao he ,wei sheng jiang
N + Y decoction 1 pack decocted
twice
bid 1. Estazolam 1mg,
qn + placebo of
CHM; 2.placebo of
CHM + placebo of
estazolamb
6 w
Notes: Abbreviations: CBT-i: cognitive behavior therapy for insomnia; CHM: Chinese herbal medicine; IM: integrative medicine; N: no, stating Chinese herbal medicine is used alone; Y: yes, stating Chinese herbal medicine is
used as an adjunct to conventional medicine; N + Y: stating there are two intervention groups, one for Chinese herbal medicine and the other for integrative medicine; d: day/days; m: month/months; w:week/weeks; y:year/years.
a There are two groups of control: pharmacotherapy and placebo.
b This is a study including four groups: Chinese herbal medicine plus placebo of pharmacotherapy, Chinese herbal medicine plus pharmacotherapy, pharmacotherapy plus placebo of Chinese herbal medicine, and placebo of
Chinese herbal medicine plus placebo of pharmacotherapy.
c When Chinese herbal medicine is used as an adjunct to conventional medicine, the control is the same as the conventional medicine in intervention group.
d The herbal ingredients are presented as Chinese pinyin. The correspondent scientiﬁc names are speciﬁed in the book “Dan Bensky, editor. Chinese Herbal Medicine: Materia Medica, Third Edition. Seattle, WA: Eastland
Press, Inc; 2004.”
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At the end of follow-up ranging from 1 week to 3 months, CHM
group had a signiﬁcantly better effect on the PSQI scores than placebo
(MD: −6.30, 95% CI: −12.58 to −0.02, I2 = 97%; n = two RCTs, 158 par-
ticipants) [63,80],, BZDs (MD: −3.61, 95% CI: −5.81 to −1.40, I2 = 97%;
n = three RCTs, 228 participants) [87,100,103], and non-BZDs (MD:
−2.70, 95% CI: −3.33 to −2.07; n = one RCT, 124 participants) [65].
The results are showed in Supplementary Fig. S1.
3.3.1.2. CHM plus conventional medicine versus control. In terms of
sleep quality assessed by the PSQI scores, the effect of CHM plus
BZDs was signiﬁcantly better than that of placebo plus BZDs (MD:
−1.88, 95% CI: −2.78 to −0.97, I2 = 0; n = three RCTs, 121 partici-
pants) [76,104,108] and BZDs alone (MD: −3.19, 95% CI: −4.40 to −1.99,
I2 = 89%; n = ﬁve RCTs, 462 participants) [48,58,79,88,109]. CHM plus
psychotherapy was more effective than psychotherapy alone (MD:
−3.80, 95% CI: −4.91 to −2.68, I2 = 68%; n = three RCTs, 372 partici-
pants) [77,78,92,111]. However, CHMplus non-BZDswas not superior
to non-BZDs alone (MD: −1.15, 95% CI: −2.49–0.19; n = one RCT, 96
participants) [91]. One RCT (193 participants) reported that CHM
plus sleep hygiene education was not superior to placebo plus sleep
hygiene education (MD: −0.81, 95% CI: −2.26–0.64) [41]. The results
are shown in Fig. 4.
At the end of a 7-day follow-up, the effect of CHM plus BZDs on
PSQI scores was not superior to placebo plus BZDs (MD: −1.43, 95%
CI: −3.04–0.18; n = one RCT, 60 participants) [108]. The results are
shown in Supplementary Fig. S2.
3.3.2. Athens Insomnia Scale
3.3.2.1. CHM alone versus control. In terms of global sleep quality
evaluated by the AIS, CHMwasmore effective than BZDs (MD: −1.42,
95% CI: −2.21 to −0.64, I2 = 63%; n = six RCTs, 463 participants)
[52,59,66,85,97,115], but notmore effective than non-BZDs (MD: 0.14,
95% CI: −0.26–0.54, I2 = 0%; n = two RCTs, 121 participants) [56,110].
The results are shown in Supplementary Fig. S3.
3.3.2.2. CHM plus conventional medication versus control. The effect
of CHM plus non-BZDs on the AIS scores was similar to that of
non-BZDs alone (MD: −0.57, 95% CI: −0.95 to −0.19, I2 = 0%; n = two
RCTs, 120 participants) [56,110]. The results are shown in Supple-
mentary Fig. S4.
3.3.3. Patient-rated sleep parameters
3.3.3.1. Sleep-onset latency. In terms of sleep-onset latency re-
ported by patients, CHM was more effective than placebo (MD:
−19.87min, 95% CI: −26.93 to −12.82min, I2 = 0%; n = three RCTs, 395
participants) [68,80,95], but not more effective than BZDs (MD:
−13.81 min, 95% CI: −31.27–3.65 min, I2 = 92%; n = three RCTs, 329
participants) [69,103,112]. There was no signiﬁcant difference
between the effect of CHM plus non-BZDs and non-BZDs alone (MD:
−1.93 min, 95% CI: −11.30–7.44 min; n = one RCT, 60 participants)
[71] or CHM plus sleep hygiene and BZDs plus sleep hygiene (MD:
−2.81 min, 95% CI: −8.17–2.55 min; n = one RCT, 193 participants)
[41]. The results are shown in Supplemental Figs. S5 and S6. At the
end of a 3-month follow-up period, participants who received CHM
reported shorter sleep-onset latency than those who received BZDs
(MD: −32.00min, 95% CI: −45.84 to −18.16min; n = one RCT, 84 par-
ticipants) [103].
3.3.3.2. Total sleep duration. In terms of total sleep duration
reported by patients, CHM was more effective than placebo
(MD: 0.78 h, 95% CI: 0.55–1.01 h, I2 = 0%; n = three RCTs, 395
participants) [68,80,95] and BZDs (MD: 1.12 h, 95% CI: 0.36–1.87,
I2 = 95%; n = seven RCTs, 783 participants) [44,45,50,69,103,105,112].
The results are shown in Supplemental Fig. S7. At the end of
a 3-month follow-up period, participants who received CHM
reported longer total sleep duration than those who received
BZDs (MD: 1.60 h, 95% CI: 1.08–2.12 h; n = one RCT, 84 partici-
pants) [103].
Fig. 2. Risk of bias in included studies. CRO: clinician-reported outcome; PRO: patient-reported outcome.
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Fig. 3. PSQI of CHM versus control. PSQI: Pittsburgh Sleep Quality Index; CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs; non-BZDs: non-benzodiazepine drugs.
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3.3.3.3. Sleep eﬃciency. In terms of sleep eﬃciency calculated from
patient-reporting sleep parameters, CHM was superior to placebo
(MD: 9.72%, 95% CI: 6.49–12.96%, I2 = 0; n = two RCTs, 294 partici-
pants) [68,95] and BZDs (MD: 19.02%, 95% CI: 18.13–19.92%, I2 = 0;
n = two RCTs, 249 participants) [68,103,112]. The results are shown
in Supplemental Fig. S8. At the end of a 3-month follow-up period,
participants who received CHM reported improved sleep eﬃcien-
cy than those who received BZDs (MD: 20%, 95% CI: 11.23–28.77%;
n = one RCT, 84 participants) [103].
3.3.4. Sleep parameters measured by PSG
Sleep parameters measured by PSG were only reported in two
RCTs. Data synthesis was not possible because the study design of
these two studies varied. According to the only one RCT (96 par-
ticipants) [94], CHM was not superior to placebo for sleep-onset
latency (MD: −1.12 min, 95% CI: −10.31–8.07 min), total sleep du-
ration (MD: 20.33 min, 95% CI: −11.78–52.44 min), sleep eﬃciency
(MD: 3.00%, 95% CI: −2.80–8.80%), or times of awakenings (MD: −0.74
times, 95% CI: −2.88–1.40 times). The four-arm, double-blind, and
double-dummy RCT (n = 33 participants) [76] reported no signiﬁ-
cant difference in sleep-onset latency, total sleep duration, sleep
eﬃciency, or times of awakenings among CHM plus placebo BZDs,
BZDs plus placebo CHM, CHM plus BZDs, and placebo CHM plus
placebo BZDs.
3.3.5. Clinician global impression
There was no signiﬁcant difference in the severity of clinician
global impression assessed by CGI-S between CHM and BZDs (MD:
0.10, 95% CI: −0.20–0.41, I2 = 0%; n = three RCTs, 236 participants)
[70,89,113] or between CHM plus BZDs and BZDs alone (MD: −0.47,
95% CI: −1.09–0.15; n = one RCT, 86 participants) [107]. The results
are shown in Supplementary Fig. S9. At the end of a 1-week follow-
up period, the CGI-S score was lower in participants who received
CHM than those who received BZDs (MD: −0.89, 95% CI: −1.41 to
−0.37; n = one RCT, 100 participants) [89].
3.4. Adverse events
Adverse events were monitored in 43 studies. Eleven of them
found no adverse events for the whole study [42,53,59,65,66,80,
88,94,95,104,108]. Data of 23 studies were available for the meta-
analysis of frequency. There was no signiﬁcant difference in the
frequency of adverse events between CHM and placebo (RR: 1.65,
95% CI: 0.67–4.10, I2 = 0; n = two RCTs, 400 participants) [68,101].
The CHM group had fewer adverse events than the BZD group (RR:
0.15, 95% CI: 0.07–0.28, I2 = 76%; n = 16 RCTs, 1802 participants)
[40,43–45,50,52,54,55,61,74,89,90,93,99,115,118] and the non-
BZD group (RR: 0.11, 95% CI: 0.02–0.58, I2 = 0; n = two RCTs, 199
participants) [39,84]. The adjunct CHM treatment did not signiﬁ-
cantly increase the frequency of adverse events associated with non-
BZDs (RR: 0.36, 95% CI: 0.10–1.27; n = one RCT, 96 participants;
n = one RCT, 96 participants) [91] or the psychotherapy group (RR:
1.58, 95% CI: 0.08–30.90, I2 = 73%; n = two RCTs, 372 participants)
[41,111]. These results are shown in Figs. 5 and 6. The most fre-
quent types of adverse events in CHM groups were digestive
dysfunction such as indigestion and mild increased defecation,
dizziness, fatigue, drowsiness, and dry mouth. However, none of
the studies assessed whether the reported adverse events were
associated with CHM.
Fig. 4. PSQI of CHM plus conventional medicine versus control. PSQI: Pittsburgh Sleep Quality Index; CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs; non-
BZDs: non-benzodiazepine drugs.
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Fig. 5. Frequency of adverse events of CHM versus control. CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs; non-BZDs: non-benzodiazepine drugs.
Fig. 6. Frequency of adverse events of CHM plus conventional medicine versus control. CHM: Chinese herbal medicine; non-BZDs: non-benzodiazepine drugs.
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3.5. Other analysis
3.5.1. Subgroup analysis of the primary outcome
The subgroup analysis based on treatment duration (≤4 weeks
or >4 weeks), insomnia history (<1 year or ≥1 year), and prepara-
tion of CHM (decoction or non-decoction) could not address the
heterogeneity of meta-analysis for the PSQI scores. The results are
shown in Table 3.
3.5.2. Sensitivity analysis
Only four studies (582 participants) had low risk of bias relat-
ing to allocation concealment and blinding of participants
[68,80,95,101]. All four studies compared non-decoction CHM treat-
ment (≤1month) with placebo. At the end of the treatment, the PSQI
score was lower in participants who received CHM treatment than
those who received placebo (MD: −2.13, 95% CI: −3.92 to −0.35,
I2 = 87%).
Eleven studies comparing CHMwith BZDs clariﬁed that they ex-
cluded the sixth domain (use of sleepmedications) when calculating
the total scores of PSQI [46,47,53,55,62,67,72,87,93,98,102]. The PSQI
scores were signiﬁcantly lower in the participants treated with CHM
than in those with BZDs (MD: −1.46, 95% CI: −2.10 to −0.81, I2 = 80%;
n = 11 RCTs, 1046 participants).
Imbalance baseline of PSQI scores was found in three studies in
two heterogeneousmeta-analyses [50,82,109]. After excluding them,
a greater reduction of PSQI scores was observed in the partici-
pants treated with CHM (MD: −1.93, 95% CI: −2.46 to −1.39, I2 = 96%;
n = 33 RCTs, 3255 participants) and CHM combined with BZDs (MD:
−2.72, 95% CI: −3.91 to −1.53, I2 = 85%; n = four RCTs, 402 partici-
pants) than in those with BZDs alone.
3.5.3. Post hoc analysis
The post hoc subgroup analysis on primary outcome was made
to explore the estimated effect of individual formula. Four formu-
lae were investigated more than twice in the included RCTs with
PSQI scores. The PSQI scores were lower in the participants treated
with the Zao Ren An Shen capsule (MD: 0.47, 95% CI: −0.43 to −1.36,
I2 = 85%; n = three RCTs, 240 participants) [54,74,83], the Xue Fu Zhu
Yu decoction (MD: −1.29, 95% CI: −2.09 to −0.49, I2 = 0; n = two RCTs,
266 participants) [62,102], and the Wuling capsule (MD: −2.34, 95%
CI: −3.45 to −1.23, I2 = 96%; n = two RCTs, 148 participants) than in
those with BZDs [64,100]. There was no signiﬁcant difference of PSQI
scores after the treatment with the Tian Wang Bu Xin pill and BZDs
(MD: −0.73, 95% CI: −2.87–1.42; I2 = 88%; n = two RCTs, 146 partici-
pants) [46,57].
3.6. Publication bias
Only the comparison between CHM and BZDs in the meta-
analysis of PSQI scores included >10 studies. The publication bias
was not detected in either the visual funnel plot (Supplementary
Fig. S10), Egger’s test (p = 0.708) or Begger’s test (p = 0.122).
4. Discussion
4.1. Evidence summary and applicability
In this study, we systematically reviewed 79 RCTs investigating
a variety of CHM treatments for participants with insomnia. We also
performed meta-analyses to estimate the eﬃcacy of CHM on sub-
jective sleep quality assessed by validated instruments, patient-
rated sleep parameters, clinician-reported severity, and PSG results,
as well as to determine the safety of CHM. This systematic review
provides up-to-date and comprehensive evidence of the eﬃcacy and
safety of CHM for insomnia. We also investigated the impact of dif-
ferent treatment strategies, subtypes of participants, various
comparators, andmethodological designs on the effect, whichmakes
our results clinically meaningful. Overall, this systematic review and
Table 3
Subgroup analysis of PSQI scores based on treatment duration, insomnia history, and preparation of CHM.
Subgroup No. study No. participants Estimated effect (MD, 95% CI) I [2] Analysis model
CHM versus BZDs
Treatment duration ≤4weeks 28 2874 −1.67 (−2.27, −1.08) 94% Random
>4 weeks 7 487 −2.95 (−3.84, −2.07) 86% Random
Duration of insomnia history <1 year 4 340 −0.55 (−2.62, 1.51) 96% Random
≥1 year 20 2144 −1.98 (−2.61, −1.34) 96% Random
Preparation of CHM Decoction 21 2175 −2.26 (−3.02, −1.50) 94% Random
Non-decoction 14 1186 −1.47 (−2.25, −0.70) 97% Random
CHM versus placebo
Treatment duration ≤4 weeks 7 796 −2.40 (−3.61, −1.19) 88% Random
>4 weeks 1 57 −7.22 (−7.86, −6.58) NA Fixed
Duration of insomnia history <1 year 1 60 −0.90 (−1.56, −0.24) NA Fixed
≥1 year 5 527 −4.21 (−6.28, −2.15) 95% Random
CHM versus non-BZDs
Duration of insomnia history ≥1 year 2 206 0.12 (−0.24, 0.48) 24% Fixed
<1 year 0 NA NA NA NA
CHM plus BZDs versus BZDs
Preparation of CHM Decoction 2 160 −4.21 (−5.75, −2.68) 82% Random
Non-decoction 2 222 −3.11 (−3.50, −2.72) 7% Fixed
Combination 1 80 −0.53 (−1.67, 0.61) NA Fixed
Duration of insomnia history ≥1 year 4 322 −3.23 (−5.16, −1.31) 92% Random
<1 year 0 NA NA NA NA
CHM plus BZDs versus BZDs plus placebo
Duration of insomnia history <1 year 1 14 0.60 (−3.48, 4.68) NA Fixed
≥1 year 2 107 −2.00 (−2.93, −1.07) 0% Fixed
CHM plus psychotherapy versus psychotherapy
Treatment duration ≤4 weeks 1 120 −3.45 (−4.54, −2.36) NA Fixed
>4 weeks 2 252 −3.77 (−5.77, −1.77) 71% Random
Preparation of CHM Decoction 2 210 −3.25 (−4.22, −2.27) 0% Fixed
Non-decoction 1 152 −4.55 (−5.02, −4.08) NA Fixed
Notes: PSQI: Pittsburgh Sleep Quality Index; CHM: Chinese herbal medicine; BZDs: benzodiazepine drugs; non-BZDs: non-benzodiazepine drugs; NA: not applicable; MD:
mean difference; CI: conﬁdential intervals. For some comparison, the subgroup analysis could not be achieved because of insuﬃcient information related to treatment du-
ration, duration of insomnia history, or preparation of CHM.
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meta-analysis showed that CHMwas superior to placebo and BZDs
when used as a monotherapy and was superior to BZDs and psy-
chotherapy alone as an adjunct therapy in terms of subjective sleep
quality and quantity and safety. CHMwas not associated with more
beneﬁt than non-BZDs, although the risks were less. These results
suggest that CHM could be a promising alternative therapy with a
good beneﬁt–risk ratio.
In this systematic review, the most homogeneous meta-analysis
of primary outcome was the comparison of CHM plus BZDs with
placebo CHM plus BZDs. It showed that the adjunct use of CHM re-
sulted in a larger reduction of PSQI scores by 1.88 points, which was
greater than the MCID of PSQI scores [33]. This result suggests that
the estimated effect of CHM as a co-intervention to BZDs is rele-
vant and potentially important to the insomnia patients in real
clinical practice.
As this systematic review only included participants primarily
diagnosed with insomnia, the evidence on CHM generated from this
systematic review cannot be generalized to the population with
comorbid insomnia or medication/substance-induced insomnia. In
addition, the longest follow-up duration of the CHM treatment was
6 months; thus, the evidence of safety related to CHM could not
be generalized to a longer therapy.
4.2. Overall completeness of evidence and clinical implications
A placebo effect is commonly observed for self-reported out-
comes related to insomnia where placebo treatment signiﬁcantly
improved the total scores of PSQI by 2.0 points, increased total sleep
duration by 23.0min, and decreased sleep-onset latency by 15.1min,
compared with no treatment [120]. In this systematic review, our
primary ﬁnding was that CHM was superior to placebo in terms of
the improvement of PSQI scores, sleep-onset latency, total sleep du-
ration, and sleep eﬃciency in participants with insomnia. In the
sensitivity analysis, the positive trend of CHM was robust after the
studies with inadequate randomization, allocation concealment, or
insuﬃcient blinding were removed. This study provides new evi-
dence of the effect of CHM on subjective insomnia. This result also
suggests that CHM could be an alternative treatment for individu-
als with insomnia when CBT-i or pharmacotherapies are unavailable
in clinical settings.
Previous studies showed that short-term use of BZDs was ef-
fective for insomnia [8]. However, the risks and side effects associated
with BZDs, such as daytime drowsiness and drug dependency, have
been noted in both research and clinical practice [9,121–123].
Another striking ﬁnding of our systematic reviewwas that CHMwas
associated with more beneﬁt in terms of subjective sleep quality,
total sleep duration, and sleep eﬃciency than BZDs, and these results
remained robust in sensitivity analysis. Furthermore, the meta-
analysis indicated that the frequency of adverse events in participants
treated with short-to-medium CHM was signiﬁcantly lesser than
that of participants treated with BZDs, and no serious adverse events
were reported in any study. These results suggest that CHM might
be an alternative to BZDs for individuals whose predominant com-
plaint is dissatisfaction with overall sleep quality and total sleep
quantity, although towhat extent CHMwas better than BZDs remains
uncertain. However, CHM did not have a better effect than non-
BZDs on subjective outcomes of insomnia, although it was associated
with less adverse events.
Insomnia management is complex as a sequential or integra-
tive approach is used, particularly for persistent and chronic insomnia
[124,125]. In this systematic review, we also investigated the add-
on effect of CHM on conventional medicine. The meta-analysis
showed that the adjunct use of CHM to conventional medicine re-
sulted in greater improvement of subjective sleep quality compared
with BZDs, non-BZDs, and CBT-i. The highest level of evidence was
attained from the homogeneous meta-analysis comparing CHM plus
BZDs with BZDs plus placebo. In addition, the adjunct use of CHM
to CBT or non-BZDs did not increase the adverse events in partici-
pants with insomnia. These results provide new knowledge that CHM
could be used as a complementary therapy for insomnia patients
with a predominant complaint of dissatisfaction with overall sleep
quality.
Drug tolerance is commonly encountered in pharmacothera-
pies for insomnia [126]. Our systematic review showed that the effect
of CHM was well sustained in the medium-to-long-term follow-
up, and this effect was signiﬁcantly better than placebo, BZDs, and
non-BZDs in terms of PSQI scores. This result also adds new knowl-
edge to the ﬁeld.
This systematic review showed that there was no signiﬁcant dif-
ference between CHM and BZRAs for increasing sleep-onset latency
or for reducing clinician-rated severity. This indicates that the con-
scientious and judicious implementation of the CHM evidence is
required in clinical practice because the effect of CHM on insom-
nia varies according to the outcome measurement.
There was insuﬃcient evidence addressing two important clin-
ical questions: (1) whether CHMwas more beneﬁcial than CBT-i for
participants with insomnia and (2) whether CHM changed the in-
somnia electrophysiology detected by PSG.
4.3. Limitations and implications for research
Proper randomization and allocation to reduce the selection bias
are necessary for an RCT. We noted that appropriate randomiza-
tion methods were only used in 34.18% of studies, and adequate
allocation concealment in 6.33%. The poor status of randomiza-
tion may be due to the low methodological quality or low report
quality. However, both are likely to exaggerate the estimate of ef-
ﬁcacy [127,128]. Therefore, prospective registration of clinical trials
and improvement of reporting quality according to CONSORT state-
ment for herbal interventions are required in the future to present
full transparency for the study design, implementation, and data-
analysis [129–131].
Insuﬃcient blinding can also lead to overestimation of the effect
size [128]. Although double blinding is encouraged in RCTs, it is dif-
ﬁcult to practice it for herbal intervention because of the different
shape, smell, taste, and administration of CHM products from phar-
macotherapy. Considering this challenge, the eﬃcacy of any CHM
product should be assessed in the comparison with placebo before
its effectiveness is evaluated by using pharmacotherapy as its com-
parator. Sixty-six different CHM treatments were found in the pool
of RCTs, but only 13 of them used placebo as comparators and only
10 used blinding. This indicates that more RCTs using placebo and
blinding are needed. In addition, only two RCTs used placebo to CHM
decoction, which suggests that the research and development of a
placebo to CHM decoction is need.
PROs such as PSQI and patient-rated sleep parameters directly
measure the core treatment beneﬁts from patients’ perspective in
a natural setting [132], which have been comprehensively ana-
lyzed in this meta-analysis. However, the treatment effect on PROs
is easily changed by insuﬃcient allocation concealment and blind-
ing [133]. In light of the diﬃculty in blinding RCTs for Chinese herbal
intervention, the increasing use of CROs such as CGI-s and CGI-I per-
formed by blinded assessors is needed to provide the overall
assessment of insomnia progression. Sleep laboratory studies such
as PSG and actigraphy should also be encouraged to explore the
mechanism of CHM’s action in sleep structures.
Heterogeneity across studies often results in unsuccessful meta-
analysis [134]. In this systematic review, we included RCTs of various
interventions to gain a broad perspective on the evidence regard-
ing the use of CHM for insomnia, and this caused heterogeneity in
some meta-analyses. In addition, clinical and methodological het-
erogeneity could not be well addressed by subgroup or sensitivity
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analysis. Therefore, most results presented in this systematic review
were the average effects of CHMon insomnia estimated by a random-
effect model, rather than the typical effect. This solution to
heterogeneity was based on the assumption that effect being esti-
mated in different CHM treatments may not be identical, but it
follows some distribution [135,136]. We noted that the effect size
of formulae varied in the post hoc analysis, which agreed with our
assumption. Therefore, further comprehensive searches and ap-
praisals of the evidence for each CHM formula for insomnia are
needed in the future.
4.4. Agreements and disagreements with other reviews
A previous high-quality systematic review with meta-analysis
on standardized CHM for insomnia also suggested that CHM was
superior to placebo and safe for individuals with insomnia [21].
However, our study is different from the previous study in four main
areas. First, the previous study used Jadad scale [137] to examine
the study quality, and it concluded that the poor methodological
quality of the studies limited their ability to draw deﬁnitive con-
clusions. However, the use of Jadad scale is increasingly discouraged
because the total score is an unreliable assessment of validity
[138–140]. We used Cochrane risk and bias instrument to assess
the domain-speciﬁc methodological quality, thus avoiding this
problem. Second, we conducted the search up to May 2014 and
therefore collected more up-to-date evidence. Third, we only in-
cluded the participants diagnosed by standard instruments of
insomnia, whereas the previous review treated insomnia as a com-
plaint, which results in a different generalized population. Fourth,
we used a comprehensive list of sleep measurements as out-
comes, which provides more information for clinical practice and
research.
5. Conclusion
Overall, oral CHM alone or when combined with routine care can
safely improve subjective sleep in people with insomnia. However,
the typical effect of CHM cannot be determinedwhen comparedwith
BRADs and CBT-i due to heterogeneity. Further systematic review
focusing on individual formula for insomnia is needed. The devel-
opment of a comparable placebo to traditional decoction is
encouraged as well to ensure the successful blinding in clinical trials.
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Appendix A
Comprehensive English search strategy
#1: Sleep Initiation and Maintenance Disorders OR Sleep Dis-
orders OR DIMS OR Early Awakening OR Nonorganic Insomnia
OR Primary Insomnia OR Secondary Insomnia OR Transient In-
somnia OR Rebound Insomnia OR Sleep Initiation Dysfunction
OR Sleep Initiation Dysfunctions OR Sleeplessness OR Insom-
nia Disorder OR Insomnia Disorders OR Insomnias OR Chronic
Insomnia OR Psychophysiological Insomnia OR Dyssomnia
#2: Traditional Chinese Medicine OR Chinese Traditional Med-
icine OR Chinese Herbal Drugs OR Chinese Drugs, Plant OR
Medicine, Traditional OR Ethnopharmacology OR Ethnomedicine
OR Ethnobotany OR Medicine, Kampo OR Kanpo OR TCM OR
Medicine, Ayurvedic OR Phytotherapy OR Herbology OR Plants,
Medicinal OR Plant Preparation OR Plant Extract OR Plants, Med-
icine OR Materia Medica OR Single Prescription OR Herbs OR
Chinese Medicine Herb OR Herbal Medicine
#3: Acupuncture ORMeridians OR Electroacupuncture ORMoxi-
bustion OR Auriculotherapy OR plum blossom OR acupressure
OR ear acupuncture OR ear acupressure OR acupuncture, ear OR
acupuncture therapy OR moxa OR laser acupuncture OR seven-
star needle OR acupuncture analgesia OR acupuncture points OR
electroacupuncture OR electroacupuncture OR TENS OR trans-
cutaneous nerve stimulation OR transcutaneous electric nerve
stimulation OR transcutaneous electrical nerve stimulation OR
electrostimulation OR electrostimulation OR pharmacopuncture
OR point injection OR catgut embedding
#4: Tai Ji OR Tai chi OR Breathing exercises OR Qi gong OR Qigong
OR Chi Kung OR Tuina OR anmo Tuina OR Chinese massage OR
cupping OR guasha OR blood letting OR bloodletting OR diet
therapy OR therapy, diet OR therapies, diet OR phlebotomy
#5: #2 OR #3 OR #4
#6: #1 AND #5
Comprehensive Chinese search strategy
#1: 入睡和睡眠障碍 OR失眠 OR 睡眠 OR 不寐;
#2:中医 OR中西医 OR中医疗法 OR辨病论治 OR辨证 OR辨证论治
OR 辨症 OR 辩证 OR 汉方 OR 祖国医学 OR 传统医学 OR 传统治疗
OR 传统疗法 OR 替代医学 OR 替代治疗 OR 中国传统医学 OR
民族医药 OR民族医学 OR草药 OR中草药 OR中药 OR中药疗法 OR
中西药 OR传统医药 OR中成药 OR植物药 OR中医治法 OR治则 OR
中医疗法 OR 熏洗 OR 薰洗 OR 药浴 OR 外洗 OR 沐足 OR 足浴 OR
浴足 OR 灌肠 OR 药熨 OR热熨 OR热敷 OR 敷脐 OR 药枕 OR 足疗
OR外敷
#3:针刺 OR针灸 OR针灸疗法 OR针灸治疗 OR灸 OR针法 OR刺法
OR体针 OR腹针OR温针 OR火针 OR电针 OR梅花针 OR水针 OR
穴位注射 OR 经络注射 OR 穴位按压 OR 穴位按摩 OR 穴位疗法 OR
指压 OR 耳压 OR 耳针OR 耳穴 OR 耳豆 OR 压豆 OR 点穴 OR 埋线
OR埋针OR头针OR眼针OR蜂针OR穴位贴敷OR小针刀OR皮肤针
#4:外治 OR外治法 OR推拿OR按摩 OR拔罐 OR药罐 OR推罐 OR
闪罐 OR 火罐 OR 针罐 OR 砭石 OR 刮痧 OR 挑治 OR 发泡 OR 导引
OR吐纳 OR气功 OR太极 OR八段锦 OR刺络 OR刺血OR刺血疗法
OR放血 OR三棱针 OR离子导入 OR理疗 OR情志疗法 OR中医音乐
OR 五行音乐
#5: #2 OR #3 OR #4
#6: #1 AND #5
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Appendix B: Supplementary material
Supplementary data to this article can be found online at
doi:10.1016/j.sleep.2015.08.012.
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